Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
Bria E, Furlanetto J, Carbognin L, Brunelli M, Caliolo C, Nortilli R, Massari F, Pedron S, Manfrin E, Pellini F, Bonetti F, Sperduti I, Pollini GP, Scarpa A, Tortora G. Bria E, et al. Among authors: tortora g. Clin Breast Cancer. 2015 Feb;15(1):16-23. doi: 10.1016/j.clbc.2014.05.004. Epub 2014 Jun 23. Clin Breast Cancer. 2015. PMID: 25034441
Emerging pathways and future targets for the molecular therapy of pancreatic cancer.
Vaccaro V, Melisi D, Bria E, Cuppone F, Ciuffreda L, Pino MS, Gelibter A, Tortora G, Cognetti F, Milella M. Vaccaro V, et al. Among authors: tortora g. Expert Opin Ther Targets. 2011 Oct;15(10):1183-96. doi: 10.1517/14728222.2011.607438. Epub 2011 Aug 7. Expert Opin Ther Targets. 2011. PMID: 21819318 Review.
Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies.
Loupakis F, Cremolini C, Salvatore L, Schirripa M, Lonardi S, Vaccaro V, Cuppone F, Giannarelli D, Zagonel V, Cognetti F, Tortora G, Falcone A, Bria E. Loupakis F, et al. Among authors: tortora g. Cancer. 2012 Mar 15;118(6):1523-32. doi: 10.1002/cncr.26460. Epub 2011 Aug 25. Cancer. 2012. PMID: 22009364 Free article.
Sorafenib for lung cancer: is the "Battle" still open?
Bria E, Pilotto S, Tortora G. Bria E, et al. Among authors: tortora g. Expert Opin Investig Drugs. 2012 Oct;21(10):1445-8. doi: 10.1517/13543784.2012.707191. Epub 2012 Jul 16. Expert Opin Investig Drugs. 2012. PMID: 22799503
Profiling mTOR pathway in neuroendocrine tumors.
Cingarlini S, Bonomi M, Corbo V, Scarpa A, Tortora G. Cingarlini S, et al. Among authors: tortora g. Target Oncol. 2012 Sep;7(3):183-8. doi: 10.1007/s11523-012-0226-9. Epub 2012 Aug 14. Target Oncol. 2012. PMID: 22890559 Review.
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status.
Bria E, De Manzoni G, Beghelli S, Tomezzoli A, Barbi S, Di Gregorio C, Scardoni M, Amato E, Frizziero M, Sperduti I, Corbo V, Brunelli M, Bersani S, Tortora G, Scarpa A. Bria E, et al. Among authors: tortora g. Ann Oncol. 2013 Mar;24(3):693-701. doi: 10.1093/annonc/mds506. Epub 2012 Nov 6. Ann Oncol. 2013. PMID: 23131390 Free article.
731 results